FIRST REPORT ON OTOTOXICITY OF MEGLUMINE ANTIMONIATE-Reference-Cited by-同舟云学术

FIRST REPORT ON OTOTOXICITY OF MEGLUMINE ANTIMONIATE

Published:2014-09 Issue:5 Volume:56 Page:439-442
ISSN:0036-4665
Container-title:Revista do Instituto de Medicina Tropical de São Paulo
language:
Short-container-title:Rev. Inst. Med. trop. S. Paulo

Author:

Valete-Rosalino Cláudia Maria¹,Araujo-Melo Maria Helena²,Bezerra Débora Cristina de Oliveira³,Barcelos Renata Oliveira de³,Melo-Ferreira Vanessa de⁴,Torraca Tânia Salgado de Sousa¹,Martins Ana Cristina da Costa⁵,Moreira João Soares⁵,Vargas Mirian Catherine Melgares⁵,Braga Frederico Pereira Bom⁵,Salgueiro Mariza de Matos⁵,Saheki Maurício Naoto⁵,Schubach Armando Oliveira⁵

Affiliation:

1. Fundação Oswaldo Cruz (IPEC-FIOCRUZ), Brazil; Universidade Federal do Rio de Janeiro (UFRJ), Brazil

2. Fundação Oswaldo Cruz (IPEC-FIOCRUZ), Brazil; Universidade Federal do Estado do Rio de Janeiro (UNIRIO), Brazil

3. Universidade Federal do Rio de Janeiro (UFRJ), Brazil

4. Fundação Oswaldo Cruz (IPEC-FIOCRUZ), Brazil; Universidade Federal do Rio de Janeiro (UFRJ), Brazil; Bolsista de iniciação científica, Brazil

5. Fundação Oswaldo Cruz (IPEC-FIOCRUZ), Brazil

Abstract

Introduction: Pentavalent antimonials are the first drug of choice in the treatment of tegumentary leishmaniasis. Data on ototoxicity related with such drugs is scarcely available in literature, leading us to develop a study on cochleovestibular functions. Case Report: A case of a tegumentary leishmaniasis patient, a 78-year-old man who presented a substantial increase in auditory threshold with tinnitus and severe rotatory dizziness during the treatment with meglumine antimoniate, is reported. These symptoms worsened in two weeks after treatment was interrupted. Conclusion: Dizziness and tinnitus had already been related to meglumine antimoniate. However, this is the first well documented case of cochlear-vestibular toxicity related to meglumine antimoniate.

Publisher

FapUNIFESP (SciELO)

Subject

Infectious Diseases,General Medicine

Link

http://www.scielo.br/pdf/rimtsp/v56n5/0036-4665-rimtsp-56-05-439.pdf

Reference19 articles.

1. Guidelines: audiologic management of individuals receiving cochleotoxic drug therapy;Practice Policy. ASHA,1994

2. Risk factors associated to dizziness during treatment for mucosal leishmaniasis with meglumine antimoniate: 16-year retrospective study of cases from Rio de Janeiro, Brazil;Araujo-Melo MH;J Laryngol Otol,2010

3. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate;Chulay JD;Trans R Soc Trop Med Hyg,1988

4. American tegumentary leishmaniasis in older adults: 44 cases treated with an intermittent low-dose antimonial schedule in Rio de Janeiro, Brazil;de Camargo Ferreira e Vasconcellos E;J Am Geriatr Soc,2010

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Self-reporting of hearing loss and tinnitus in the diagnosis of ototoxicity by meglumine antimoniate in patients treated for American tegumentary Leishmaniasis;PLOS ONE;2024-02-14

2. Antiparasitic Agents for Pediatric Infections, and Hearing Loss;Hearing Loss in Congenital, Neonatal and Childhood Infections;2023

3. Alterations in Evoked Otoacoustic Emissions by the Use of Meglumine Antimoniate in American Tegumentary Leishmaniasis Patients;PLOS ONE;2017-01-03

4. Multiple drugs;Reactions Weekly;2014-10